SCHEMBL9861628

SCHEMBL9861628

CCCc1ccc(C(=O)c2ccc(CCC)cc2)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLK1 P53350 2/20 0.64
THRB P10828 3/20 0.62
L3MBTL1 Q9Y468 1/20 0.60
CNR2 P34972 1/20 0.58
GAA P10253 4/20 0.56
ALDH1A1 P00352 3/20 0.56
POLB P06746 3/20 0.56
CTDSP1 Q9GZU7 3/20 0.56
KDM4E B2RXH2 1/20 0.56
NPC1 O15118 3/20 0.55
RAB9A P51151 3/20 0.55
KMT2A Q03164 2/20 0.55
MAPT P10636 1/20 0.55
ESR1 P03372 1/20 0.53
ESR2 Q92731 1/20 0.53
LMNA P02545 1/20 0.53
TDP1 Q9NUW8 1/20 0.53
BDKRB2 P30411 1/20 0.50
RARB P10826 1/20 0.50
LPL P06858 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4605419 0.92 L3MBTL1 (0.58) PLK1THRBL3MBTL1CNR2GAA
SCHEMBL27449104 0.92 ALDH1A1 (0.64) PLK1THRBL3MBTL1CNR2GAA
Benzophenone SCHEMBL28417175 0.92 L3MBTL1 (0.58) PLK1THRBL3MBTL1CNR2GAA
SCHEMBL9099918 0.90 PLK1 (0.55) PLK1THRBL3MBTL1CNR2GAA
SCHEMBL31164297 0.90 POLB (0.72) PLK1THRBL3MBTL1CNR2GAA
SCHEMBL28927088 0.88 PLK1 (0.53) PLK1THRBL3MBTL1CNR2GAA
SCHEMBL13746337 0.87 PLK1 (0.51) PLK1THRBL3MBTL1CNR2GAA
SCHEMBL10014123 0.87 RAB9A (0.58) PLK1THRBCNR2GAAALDH1A1
SCHEMBL1404028 0.86 RARB (0.67) PLK1THRBCNR2ALDH1A1KMT2A
SCHEMBL21514119 0.85 PLK1 (0.50) PLK1THRBL3MBTL1CNR2GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110891562-B Lithium salts of N-substituted glycine compounds and uses thereof 心悦生医股份有限公司 2024-07-16 CN claimed
CN-113347965-B TGF-beta inhibitors and prodrugs 生物医学研究机构基金会 2025-02-18 CN disclosed
CN-110891562-B Lithium salts of N-substituted glycine compounds and uses thereof 心悦生医股份有限公司 2024-07-16 CN disclosed
CN-118001260-A Dissolving monosodium urate for treating gout 贺亮 2024-05-10 CN disclosed
CN-111479806-B D-amino acid oxidase inhibitors and therapeutic uses thereof 心悦生医股份有限公司 2024-01-30 CN disclosed
CN-111491625-B Dissolving monosodium urate for treating gout 贺亮 2023-12-01 CN disclosed
CN-110944644-B Anti-inflammatory compositions comprising novel quercetin compounds 株式会社爱茉莉太平洋 2023-06-13 CN disclosed
CN-110769833-B Anti-inflammatory composition comprising kaempferol compounds derived from post-fermented tea 株式会社爱茉莉太平洋 2023-05-12 CN disclosed
CN-109627152-B Photocatalytic synthesis method and application of cyclohexyl- (4-R phenyl) ketone compound 甘肃金盾化工有限责任公司 2022-01-25 CN disclosed
CN-109641814-B Non-corrosive nitration inhibitor polar solvent preparation 美国陶氏益农公司 2021-12-31 CN disclosed
CN-111225946-A Thermal interface compositions comprising ionically modified siloxanes 莫门蒂夫性能材料股份有限公司 2020-06-02 CN disclosed
CN-109627152-A A kind of photocatalytic synthesis method of cyclohexyl-(4-R phenyl) first ketone compounds and its application 甘肃金盾化工有限责任公司 2019-04-16 CN disclosed
CN-109369406-A A kind of photocatalytic synthesis method of 1- hydroxycyclohexyl phenyl ketone class compound and its application 甘肃金盾化工有限责任公司 2019-02-22 CN disclosed
US-9206125-B2 Use of compound binding to mSin3B that specifically binds to neuron restrictive silencer factor (NRSF) PUBLIC UNIVERSITY CORPORATION YOKOHAMA CITY UNIVERSITY (JP) 2015-12-08 US disclosed
US-20130203738-A1 USE OF COMPOUND BINDING TO MSIN3B THAT SPECIFICALLY BINDS TO NEURON RESTRICTIVE SILENCER FACTOR (NRSF) NAGOYA CITY UNIVERSITY (JP) 2013-08-08 US disclosed
EP-0032062-B2 HIGH-MOLECULAR-WEIGHT NOVOLAK SUBSTITUTED PHENOLIC RESINS AND THEIR PREPARATION MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) 1991-10-16 EP disclosed
EP-0032062-B1 HIGH-MOLECULAR-WEIGHT NOVOLAK SUBSTITUTED PHENOLIC RESINS AND THEIR PREPARATION MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) 1985-04-03 EP disclosed
US-4497887-A Thermal development type diazo copying material with hydrophobic resin encapsulated coupler particle Ricoh Compay, Ltd. (JP) 1985-02-05 US disclosed
EP-0032062-A2 High-molecular-weight novolak substituted phenolic resins and their preparation MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) 1981-07-15 EP disclosed
US-4042587-A PESTICIDES BASF AKTIENGESELLSCHAFT (DT) 1977-08-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130203738-A1 USE OF COMPOUND BINDING TO MSIN3B THAT SPECIFICALLY BINDS TO NEURON RESTRICTIVE SILENCER FACTOR (NRSF) RCOR1, MSI2, RCOR3 PLK1 4112/4885THRB 705/4885L3MBTL1 733/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.